Skip to main content

Table 1 Study characteristics of included studies

From: Association of hormone replacement therapy with mortality in colorectal cancer survivor: a systematic review and meta-analysis

Study

Study period

Country

Age

Number of participants

Stage

Grade

HRT Type

HRT recency

CRC death/HRT user

All-cause death /HRT user

Mean follow-up year

Prospective cohort

 Arem et al. (2015) [13]

1995–2011

USA

50–71

2053

30.5% localized, 31.3% regional or distant, 38.2% unknown

12.0% well-differentiated, 57.5% moderate-differentiated, 0.9% undifferentiated, 29,6% unknown

E, E + P

Current, former

Current (98/670), former (36/201)

Current (214/670), former (87/201)

7.7

 Chan et al. (2006) [14]

1976–2004

USA

62.2–65.7a

834

22.3% stage I, 26.1% stage II, 25.5% stage III, 15.6% stage IV, 10.5% unknown

22.3% stage I, 26.1% stage II, 25.5% stage III, 15.6% stage IV, 10.5% unknown

E, E + P

Current, former

Current (64/235), former (83/229)

Current (87/235), former (103/229)

5–10

 Mandelson et al. (2003) [15]

1980–1998

USA

50–79

699

NR

NR

E, E + P

Current

Current (18/103)

Current (37/103)

5.33

 Slattery et al. (1999) [16]

1991–1998

USA

55–79

801

35.4% local, 53.2% regional, 11.4% distant

NR

E, E + P

Current to stop less than 5 years

Current to stop less than 5 years (NR/186)

Current to stop less than 5 years (46/186)

4.0

Retrospective cohort

 Ji et al. (2018) [17]

2006–2015

Sweden

45–69

5626

23.7% stage I, 27.8% stage II, 36.2% stage III, 12.3% stage IV

NR

E, E + P

Current

Current (NR/1109)

Current (246/1109)

5.4

Study

Variables adjusted

Exposure assessment

Mortality ascertainmentb

        

Prospective cohort

 Arem et al. (2015) [13]

Years from questionnaire to diagnosis, BMI, marital status, smoking status, diabetes, physical activity, cancer stage, tumor grade, and receipt of chemotherapy, radiation, and surgery

Questionnaire

Social Security Administration Death Master File and the National Death Index Plus

        

 Chan et al. (2006) [14]

Age at diagnosis, year of diagnosis, cancer site (colon, rectum, or unknown), BMI, aspirin use at diagnosis, smoking status, postdiagnosis physical activity, cancer stage, tumor grade, and receipt of chemotherapy

Questionnaire

National Death Index and physician reviewer

        

 Mandelson et al. (2003) [15]

Age at diagnosis; year of diagnosis; and cancer stage

Group Health Cooperative computerized pharmacy database

Western Washington SEER registry

        

 Slattery et al. (1999) [16]

Age at diagnosis, study center, BMI, and cancer stage

In-person interview

Local tumor registries

        

Retrospective cohort

 Ji et al. (2018) [17]

Age at diagnosis; year of diagnosis, country of birth (Sweden, European countries and others), highest educational level, family history of CRC, comorbidities with chronic ischemic heart disease, type 2 diabetes, chronic obstructive pulmonary disease and hypertension; and cancer stage

Swedish Prescribed Drug Register

Cause of Death Register

        
  1. aThis study provided median age of postmenopausal participants. bCauses of death and their corresponding International Classification of Diseases and Related Health Problem, 9th and 10th version (ICD-9 and ICD-10) codes were death due to colorectal cancer (ICD-9153, 154, and 159.0; and ICD-10 C18–C20, and C26), and death due to all the causes (ICD-9001–999 and ICD-10 A00–Z99). HRT hormone replacement therapy, CRC colorectal cancer, E estrogen therapy, E + P combined estrogen progesterone therapy, NR not reported, BMI body mass index, SEER Surveillance, Epidemiology, and End Results Program